Mesenchymal stem cell-derived extracellular vesicles: Hype or hope for skeletal muscle anti-frailty

Document Type

Article

Publication Date

4-1-2023

Abstract

Steadily rising population ageing is a global demographic trend due to the advancement of new treatments and technologies in the medical field. This trend also indicates an increasing prevalence of age-associated diseases, such as loss of muscle mass (sarcopenia), which tends to afflict the older population. The deterioration in muscle function can cause severe disability and seriously affects a patient's quality of life. Currently, there is no treatment to prevent and reverse age-related skeletal muscle ageing frailty. Existing interventions mainly slow down and control the signs and symptoms. Mesenchymal stem cell-derived extracellular vesicle (MSC-EV) therapy is a promising approach to attenuate age-related skeletal muscle ageing frailty. However, more studies, especially large-scale randomised clinical trials need to be done in order to determine the adequacy of MSC-EV therapy in treating age-related skeletal muscle ageing frailty. This review compiles the present knowledge of the causes and changes regarding skeletal muscle ageing frailty and the potential of MSC-EV transplantation as a regenerative therapy for age-related skeletal muscle ageing frailty and its clinical trials.

Keywords

mesenchymal stem cell, extracellular vesicles, ageing, frailty, skeletal muscle

Publication Title

International Journal of Molecular Sciences

Divisions

biomedengine

Funders

Universiti Kebangsaan Malaysia [GUP-2020-024]

Volume

24

Issue

9

Publisher

MDPI

Publisher Location

ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND

This document is currently not available here.

Share

COinS